Nina Chu, Director, Oncology Cell Therapy at AstraZeneca, shared a post on LinkedIn:
“Exciting to see our collaborative work on armored CAR T in solid tumors published in Nature.
It’s a good reminder of how progress in science depends on strong partnerships – bringing together different expertise to better understand challenges like the tumor microenvironment in solid tumors.
Grateful to be part of AstraZeneca and to work alongside such dedicated teams and great collaborators to move this field forward.”
Title: A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma
Authors: Aditi Saha, Junmin Whiting, Razan Mohty, Kristen Flores, Jongphil Kim, Taiga Nishihori, Julio Chavez, Sameh Gaballa, Farhad Khimani, Hien Liu, Bijal Shah, Marian Dam, Muhammad Jaffer, Sepideh Mokhtari, Nima Ghalehsari, Hany Elmariah, Christina Bachmeier, Jose Alejandro Guevara, Heather Jim, Sayeef Mirza, Brahm H. Segal, Doris K. Hansen, Nelli Bejanyan, Fabiana Perna, Rawan Faramand, Michael Jain, Frederick Locke, Aleksandr Lazaryan
Other articles about CAR T on OncoDaily.